About
KRAS G12C
in Advanced NSCLC
Actor portrayal.
ABOUT KRAS G12C IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Gene mutations can lead to the development of NSCLC.
Lung cancer is a cancer that starts in the lungs. The type of lung cancer you have—NSCLC—develops from mutations in lung cells. The KRAS G12C mutation is one of many mutations that may be found in NSCLC.
KRAS G12C is a common mutation.
In healthy lungs:
KRAS is a normal gene that makes a protein that is found in many healthy cells in the body, including lung cells.
This protein works like an on/off switch, telling cells when to start and stop growing.
In lungs with KRAS G12C-positive NSCLC:
Genetic mutations can change the KRAS protein into KRAS G12C, an abnormal form stuck in the “on” position.
This can cause a domino effect where cells continue growing into tumors and can lead to cancer.
"Get an understanding of your biomarker mutations and use that to make sure you find the best possible treatment approach."
—KRAZATI TRIAL PARTICIPANT. Individual results may vary.
ABOUT BIOMARKER TESTING FOR NSCLC
Knowing your biomarker status can help your doctor find the best treatment approach for you.
Your cancer may have biomarkers that can be identified through testing. Biomarker testing is a way to look for genes and proteins that can provide more information about your unique cancer and help your doctor to choose the best treatment approach for you.
Your doctor can test you by using a biopsy, either tissue from your tumor (a tissue-based test) or blood (a liquid biopsy test). Your doctor may have already tested you when you were first diagnosed and can look back to check for your KRAS G12C status.
Don’t wait any longer to get the knowledge you deserve.
Ask your doctor these three simple questions:
|
If your advanced lung cancer is KRAS G12C-positive, your next move is simple. Ask your doctor if a targeted therapy like KRAZATI may be right for you.
KRAS=Kirsten rat sarcoma viral oncogene homolog; NSCLC=non-small cell lung cancer.
